On April 20, 2026, the FDA published a Federal Register notice (2026-07615) inviting holders of approved testosterone replacement therapy NDAs to submit supplemental applications for a new indication: treatment of low libido in men with idiopathic hypogonadism. The notice gives sponsors until April 30, 2026 to contact the agency for further guidance, signaling the most concrete pathway yet to a sexual-function-specific TRT label since the FDA's December 2025 expert panel recommended easing access.

Why It Matters

If a TRT product receives FDA approval for low libido in idiopathic hypogonadism, telehealth platforms like Hims, Ro, and BlueChew gain a labeled indication for the symptom they have been monetizing off-label for years — significantly easing FTC and state-AG scrutiny of marketing claims. Insurance coverage would expand. The opaque "low T" supplement market, currently dominated by FDA enforcement targets like Tongkat Ali and Boner Bear, would face direct regulated competition. And the cultural framing of low libido as a treatable medical condition — not an embarrassing personal failing — gets the same FDA imprimatur that Viagra got in 1998 for ED.

Idiopathic hypogonadism is defined as low serum testosterone without an underlying medical cause — historically a contested diagnosis because the FDA's existing TRT labels cover only "classical" hypogonadism caused by identified pituitary or testicular conditions. The new pathway would acknowledge that millions of men with low testosterone and impaired sexual function fall outside the classical definition and have therefore been treated off-label or shut out of insurance coverage entirely. The notice cites the December 2025 expert panel and a literature review supporting libido outcomes as the basis for moving forward.

Industry response has been swift. Statnews reported on April 17 that the FDA decision was viewed as a significant regulatory shift, and the Endocrine Society, AUA, and Urology Care Foundation submitted supportive comments. HIMS stock has gained throughout April on the cumulative weight of the testosterone, peptide, and Novo Nordisk policy developments — JPMorgan initiated coverage at Overweight on April 24 with a $35 price target. Sponsors of currently approved TRT products including AbbVie (AndroGel), Marius Pharmaceuticals (KYZATREX, Hims's branded oral testosterone partner), Acerus Pharmaceuticals, and Endo Pharmaceuticals are expected to engage.

The agency has emphasized that any new indication will require substantial evidence of safety and effectiveness. Approval is not automatic — the supplemental NDA process can take 12–24 months and will require well-controlled trials demonstrating the libido benefit. But the pathway itself is unprecedented: the FDA has not before invited sponsors to pursue a sexual-function-specific testosterone indication.

Sources

Update — 2026-04-25

Initial entry — story first created.